International Lung Cancer Study: How We Reached 100% of Our Recruitment Scope Seven Months Ahead Of Schedule

One of the world's leading biopharmaceutical companies with Korean origins ran a clinical trial for its own biosimilar product in 13 countries. palleos healthcare was contracted as a local CRO and was responsible for running full-scale clinical trial activities with the recruitment goal of 254 patients across 21 research sites. Whereas the Global CRO recruited 509 patients at 79 sites in countries, including Germany, Spain, Serbia, Georgia, South Korea, and Taiwan.

This was a Phase III, randomized, comparative, double-blind, two-parallel group, multicenter study in subjects with metastatic or recurrent non-squamous non-small cell lung cancer. The aim of the study was to demonstrate the efficacy, safety, pharmacokinetics, and immunogenicity of the investigational drug (biosimilar) compared to a comparator during a 24-week chemotherapy period.